Editas Medicine Inc

NASDAQ:EDIT 3:59:54 PM EDT

10.96

+0.24 (+2.24%)

Products

Editas Medicine Receives FDA Orphan Drug Designation For Beta Thalassemia Treatment

Published: 05/12/2022 20:48 GMT

Editas Medicine Inc (EDIT) - Editas Medicine Receives FDA Orphan Drug Designation for Edit-301 for the Treatment of Beta Thalassemia.
Expects to Initiate a Phase 1/2 Study of Edit-301 in Patients With Transfusion Dependent Beta Thalassemia in 2022.